Last close As at 05/08/2026
CHF50.70
▲ 0.20 (0.40%)
Market capitalisation
CHF681m
Research: Healthcare
Basilea Pharmaceutica has announced that it will in-license a pre-clinical programme of novel broad spectrum anti-fungals targeting difficult-to-treat mould infections. Although the financial implications are limited, this is the first step in management’s plans announced in February to strategically refocus on its core anti-infective business while exploring strategic options for its oncology assets.
Written by
Basilea Pharmaceutica |
Spring into a new strategy |
Company newsflow |
Pharma & biotech |
28 April 2022 |
Share price performance
Business description
Analysts
Basilea Pharmaceutica is a research client of Edison Investment Research Limited. |
||||||||||||||||||||||||||||||||||||
Basilea Pharmaceutica has announced that it will in-license a pre-clinical programme of novel broad spectrum anti-fungals targeting difficult-to-treat mould infections. Although the financial implications are limited, this is the first step in management’s plans announced in February to strategically refocus on its core anti-infective business while exploring strategic options for its oncology assets.
Year end |
Revenue (CHFm) |
PBT* (CHFm) |
EPS* |
DPS |
P/E |
Yield |
12/19 |
134.4 |
(22.4) |
(207.5) |
0.0 |
N/A |
N/A |
12/20 |
127.6 |
(29.6) |
(288.5) |
0.0 |
N/A |
N/A |
12/21 |
148.1 |
(6.61) |
(56.9) |
0.0 |
N/A |
N/A |
Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.
Basilea announced a new global and exclusive in-licensing deal with US-based Fox Chase Chemical Diversity Center. This arrangement is for a preclinical programme of novel broad-spectrum antifungals with activity against difficult-to-treat mould infections. No financial details were disclosed and FY22e financial guidance remains unchanged.
We view the deal to be consistent with the new strategy presented by management to focus on building a new pipeline in the anti-infectives space to bolster its foothold with Cresemba and Zevtera. Further, we see Basilea continuing this path with more in-licensing activity focused on difficult-to treat infections. This strategy is, in our view, supported by a large unmet need to treat serious infections combined with the increasing rise of antibiotic resistance. In turn, this has spurred a renewed industry interest.
With increasing levels of antibiotic resistance (eg MRSA), we have seen a renewed industry focus on anti-infectives with several competitor candidates in clinical trials (Phase II) including: Afabicin (Debiopharm) in anti-bacterial skin and skin structure infections, Brilacidin (Innovation Pharmaceuticals) in MRSA infections and Olorofim (F2G) for invasive aspergillosis, coccidioidomycosis and invasive moulds.
|
|
Research: TMT
1Spatial’s (SPA’s) FY22 reported results surpassed our expectations. Revenues grew 10% to £27m with annualised recurring revenues up 26% (constant currency) to £13.4m, while SPA reported its first group profit before tax in over a decade. SPA’s results were driven by record contract wins across both new and existing customers, ongoing development of smart partnerships and expansion in the key US market. While it trades at a sizable discount to its software peers, we see opportunities to reduce the gap if it continues executing on its growth strategy.